Global Darbepoetin Alfa Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Darbepoetin Alfa market size was valued at US$ 4893 million in 2024 and is forecast to a readjusted size of USD 4039 million by 2031 with a CAGR of -2.7% during review period.

Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.

The classification of Darbepoetin Alfa includes Epogen, Procrit, Aranesp and others, and the proportion of Epogen in 2017 is about 45%.

Darbepoetin Alfa is widely used for Patients with Chronic Kidney Disease, Patients with Cancer others. The most proportion of Darbepoetin Alfa is used for the Patients with Chronic Kidney Disease, and the proportion in 2017 is 62%.

North America is the largest consumption place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 41%.

Market competition is not intense. Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Novartis and 3SBio etc. are the leaders of the industry, with about 87% market shares.

This report is a detailed and comprehensive analysis for global Darbepoetin Alfa market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Darbepoetin Alfa market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Darbepoetin Alfa market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Darbepoetin Alfa market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Darbepoetin Alfa market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Darbepoetin Alfa

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Darbepoetin Alfa market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Novartis, 3SBio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Darbepoetin Alfa market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Epogen
Procrit
Aranesp
Others

Market segment by Application
Patients with Chronic Kidney Disease
Patients with Cancer
Others

Major players covered
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Novartis
3SBio

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Darbepoetin Alfa product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Darbepoetin Alfa, with price, sales quantity, revenue, and global market share of Darbepoetin Alfa from 2020 to 2025.

Chapter 3, the Darbepoetin Alfa competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Darbepoetin Alfa breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Darbepoetin Alfa market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Darbepoetin Alfa.

Chapter 14 and 15, to describe Darbepoetin Alfa sales channel, distributors, customers, research findings and conclusion.